about
Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceAnti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with PsoriasisIncidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.Opposing Effects of Zac1 and Curcumin on AP-1-Regulated Expressions of S100A7Current status and future prospects for biologic treatments of psoriasis.Sustained PASI, DLQI and EQ-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Psoriasis: to treat or to manage?Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say?Ixekizumab for treatment of psoriasis.Systemic methotrexate for the treatment of psoriasis.Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective.Targeting IL-17 with ixekizumab in patients with psoriasis.Adalimumab: A Review in Chronic Plaque Psoriasis.Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.Secukinumab in the treatment of psoriasis: an update.Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases.Predictors of long-term drug survival for infliximab in psoriasis.An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).Refractory Psoriasis Vulgaris with Itching Successfully Treated with the Anti-interleukin-17A Antibody Secukinumab: A Case of Secondary Failure of Other Biologic AgentsClassification model of amino acid sequences prone to aggregation of therapeutic proteins.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Drug survival of biologic treatments in psoriasis: a systematic review.Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.Umbilical cord blood stem cell treatment for a patient with psoriatic arthritis.Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.Safety of biologics in psoriasis.
P2860
Q26798357-3412CE82-AED3-4008-9C75-E942CC7B36F5Q28554923-C3135D57-D676-4862-A9C5-73F5AD8FD92DQ30235581-81A2DBC8-5429-4EC7-9820-1B9C61C80AF6Q30240229-F2F0B019-ACDF-48F5-B042-BC7A1217FC3DQ35840998-C43BEB7E-73C6-4097-981B-4018EC42ED39Q35860140-6A0C3E6D-3E9C-4F1E-AEC8-CBF3AD2C725CQ36057909-714C4257-DEA2-4D0C-9EF6-14B2B1677835Q36413344-6A0DEEC1-D5DC-4D48-8299-058FCDFB811EQ37138974-17C7AE0A-BF19-474B-ABFE-F496AAB910A3Q37171259-49E965DA-50EC-4E4D-93A5-7F4A3420DF98Q37295966-1DDAD7AA-255E-4899-979F-DABC8D3BC392Q37352347-D0085EF1-6E59-4E46-B721-D519812A6A2EQ38210780-D0F6538B-401E-48FC-BEC9-75F09CABB4AEQ38229869-B43A3E78-1EBF-4654-A904-B7B754FD8FC5Q38369782-1D104D9A-72D2-4AAA-8347-D0B9CD1C4127Q38380882-61233557-ED82-45C1-8337-84242AAFD7D4Q38473460-BA31F8B4-DCA8-4F08-9DC2-D19F0A527ABDQ38594683-09AB2AB8-E831-4DC6-848F-6BADD3946D71Q38633741-66758460-8001-4D07-8972-E1FA28625076Q38639495-A1A15843-9F77-4EC2-A277-0AA6F6841C36Q38693563-E374B269-7657-4A94-9982-001565A3E607Q38831055-45B12C8C-A70A-49F6-B576-D760A3038ED0Q38838470-56B0494F-ACFF-4FCE-A6F9-03121489F1DBQ38940190-5C846E79-7AE5-4774-8409-379559124758Q38993275-63E4094C-D8CB-48E9-8B32-17AD287B56EFQ39120166-3FB9A058-736E-450E-ADD7-7C91BCB4FDE4Q39347886-392FED5F-C5DF-4246-A42F-024D38461532Q39453926-7D754E21-7F54-455E-AB26-7CDE4DC14DECQ39668241-DDA65C30-0F95-4F2E-BCC6-0DD77F292797Q40686340-A6999658-1E9E-4527-85A9-0E81C3A36C47Q41129456-5185E096-BCBC-4AB0-AA6E-9622D73F1FC5Q42428682-5904D5A6-92F1-4EC8-8E44-46A109353473Q44581309-DF5414D8-5968-4950-892D-02A2A968F82BQ46118586-A983D891-A552-4F11-8747-40600F1F9075Q46453213-21A21581-6499-4268-B3B9-D40872978282Q47409766-C680649D-0552-42E1-8741-EA4C923367A6Q47602890-71F70BCF-DC8C-45C8-BBEA-BBFE5CC63D11Q47737814-754D96BF-11FB-4863-8A15-8A465F57DF44Q48023865-9DB0CBAB-2689-4950-9019-7FFC7551E0E1Q48144965-BB4BB915-00E2-4BBC-BA78-B5617DE402C9
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Antidrug antibodies in psoriasis: a systematic review.
@en
type
label
Antidrug antibodies in psoriasis: a systematic review.
@en
prefLabel
Antidrug antibodies in psoriasis: a systematic review.
@en
P2093
P2860
P356
P1476
Antidrug antibodies in psoriasis: a systematic review.
@en
P2093
A W Armstrong
B T Snodgrass
P2860
P304
P356
10.1111/BJD.12654
P407
P577
2014-02-01T00:00:00Z